Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Maze Therapeutics (Nasdaq: MAZE) announced that CEO Jason Coloma, Ph.D. will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 10:30 a.m. ET.

Rhea-AI Summary

Maze Therapeutics (Nasdaq: MAZE) announced that CEO Jason Coloma, Ph.D. will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 10:30 a.m. ET.

A live webcast will be available in the Investors section of the Maze Therapeutics website and will be archived for 60 days after the presentation.

Argus Feb 25 session

+4.26% close to close Open Argus

Details

News Market Reaction – MAZE

On Feb 25, the day this news came out, MAZE closed 4.26% above the previous close.

Data tracked by StockTitan Argus for the Feb 25 session.

Key Figures

Conference date: March 4, 2026 Presentation time: 10:30 a.m. ET Webcast archive period: 60 days

Conference date

March 4, 2026

TD Cowen 46th Annual Health Care Conference presentation date

Presentation time

10:30 a.m. ET

Scheduled start time for Maze CEO presentation

Webcast archive period

60 days

Length of time conference webcast will remain available

Historical Context

5 past events · Latest: Feb 04

5 events

1. Feb 04

   Investor conference

   24h Move

   +0.3%

   Announcement of CEO presentation at Guggenheim biotech summit with webcast access.

2. Jan 05

   Investor conference

   24h Move

   -2.9%

   CEO presentation scheduled for the 44th Annual J.P. Morgan Healthcare Conference.

3. Nov 06

   Earnings & pipeline

   24h Move

   -3.5%

   Q3 2025 financials plus positive Phase 1 data and Phase 2 plans for key programs.

4. Nov 06

   Scientific conference

   24h Move

   -2.1%

   Seven ASN Kidney Week abstracts highlighting MZE829 and MZE782 mechanistic and translational data.

5. Nov 04

   Multiple conferences

   24h Move

   -2.5%

   Participation in four investor conferences with webcast availability across Nov–Dec 2025.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

small molecule, precision medicines

2 terms

small molecule medical

"a clinical-stage biopharmaceutical company developing small molecule precision medicines"

A small molecule is a low-weight chemical compound that can enter cells easily and interact with specific proteins or biological pathways to change how they work, much like a small key fitting into a lock. Investors care because small molecules are a common and often faster route to develop medicines, can be manufactured at scale, and may offer clearer regulatory and commercial paths compared with larger biologic therapies, affecting potential costs, timelines and returns.

precision medicines medical

"developing small molecule precision medicines for patients with kidney and metabolic diseases"

Precision medicines are treatments designed to work for specific groups of patients identified by genetic, biological, or lifestyle characteristics, rather than a one-size-fits-all drug. They matter to investors because these therapies can be more effective and command premium pricing in smaller, well-defined markets—offering higher potential returns if successful but also concentrated development and regulatory risk, like betting on a tailored suit that fits only certain people.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the TD Cowen 46^th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 a.m. ET.

A live webcast of the event will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 60 days following the presentation.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases, including obesity. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor advancing to Phase 2 with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow the company on LinkedIn and X.

IR/Corporate Contact:
Amy Bachrodt, Maze Therapeutics
abachrodt@mazetx.com

Media Contact:
Amanda Lazaro, 1AB Media
Amanda@1ABMedia.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Maze Therapeutics (MAZE) present at the TD Cowen 46th Annual Health Care Conference?

Maze Therapeutics will present on March 4, 2026 at 10:30 a.m. ET. According to the company, CEO Jason Coloma, Ph.D., will deliver the presentation and participate in the scheduled session during the conference.

How can investors watch the MAZE presentation at the TD Cowen conference on March 4, 2026?

Investors can watch via a live webcast on the company's investor website. According to the company, the webcast will be accessible in the Investors section at www.mazetx.com.

Will the Maze Therapeutics (MAZE) webcast be available after the live TD Cowen presentation?

Yes, the webcast will be archived for 60 days following the presentation. According to the company, the archived recording will remain available in the Investors section of the Maze website for that period.

Who from Maze Therapeutics will present at the March 4, 2026 TD Cowen conference?

Jason Coloma, Ph.D., chief executive officer, will present at the session. According to the company, he will represent Maze Therapeutics and discuss the company's progress at the conference.

What topics will Maze Therapeutics (MAZE) likely cover in the TD Cowen March 4, 2026 presentation?

The presentation will focus on company developments and clinical-stage programs in kidney and metabolic diseases. According to the company, the CEO will discuss program updates and the company's strategic priorities for investors.

Where on the Maze Therapeutics website can I find the TD Cowen conference webcast for MAZE?

The webcast is available in the Investors section of the Maze Therapeutics website at www.mazetx.com. According to the company, both the live stream and a 60-day archived recording will be posted there.